Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:1.6.5.2 (
NQO1
)
6,196
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Non-small-cell lung cancer (NSCLC) is one of the most common malignant tumors in the world. Reactive oxidative species (ROS) and nuclear factor-related factor 2 (Nrf2) -antioxidant response element (ARE) signal pathway are known to play important roles in the development of NSCLC. In this study, we identified
Peroxiredoxin 5
(
PRDX5
) as a novel binding partner for Nrf2.
PRDX5
was significantly increased in human NSCLC specimens and cell lines. Nrf2 interacted with
PRDX5
in H
2
O
2
-stimulated NCSLC cells, and the interaction promoted the expression of NAD(P)H: quinone oxidoreductase 1 (
NQO1
) protein in NSCLC cells. Further, high expression of Nrf2 and
PRDX5
were associated with worsened prognosis in patients with NSCLC significantly. Moreover, animal studies showed that the growth of tumors treated with Nrf2 and
PRDX5
shRNA was significantly lower than that of the other groups. All these data indicated that overexpressed
PRDX5
in NSCLC promoted binding with Nrf2 and enhanced
NQO1
expression and NSCLC development. Overall, our studies demonstrated that
PRDX5
can be a novel binding partner of Nrf2 in promoting NCSLC development under oxidative stress and provide potential opportunity for improving NSCLC therapy.
...
PMID:PRDX5 as a novel binding partner in Nrf2-mediated NSCLC progression under oxidative stress. 3189 87
